Complexa, a US-based biopharmaceutical spinout from University of Pittsburgh, closed a $62m series C round on Wednesday co-led by Pfizer Venture Investments, the investment arm of pharmaceutical company Pfizer, and VC firm New Enterprise Associates (NEA).
Edmond de Rothschild Investment Partners, HBM Healthcare Investments and Jafco also contributed to the round, as did unnamed existing backers.
Founded in 2012, Complexa is working on a therapy called CXA-10 for focal segmental glomerulosclerosis, an orphan disease affecting the kidney, and for pulmonary…